Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tumor Microenvironment Mechanism of LY007 Cell Injection for the Treatment of Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma and the Exploration of Novel CAR-T Translational Research

NCT06049381 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06049381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06049381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tumor Microenvironment Mechanism of LY007 Cell Injection for the Treatment of Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma and the Exploration of Novel CAR-T Translational Research
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2023
Completion date
December 31, 2025
Enrollment
22 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed non-hodgkin lymphoma